We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

148 hedge funds and large institutions have $1.47B invested in Kite Pharma, Inc. in 2015 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 56 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 18

81% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 31

28% more funds holding

Funds holding: 116148 (+32)

24% more capital invested

Capital invested by funds: $1.18B → $1.47B (+$285M)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

8% less call options, than puts

Call options by funds: $20.4M | Put options by funds: $22.3M

Holders
148
Holders Change
+32
Holders Change %
+27.59%
% of All Funds
3.94%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
51
Increased
56
Reduced
31
Closed
18
Calls
$20.4M
Puts
$22.3M
Net Calls
-$1.86M
Net Calls Change
+$3.02M
Name Holding Trade Value Shares
Change
Change in
Stake
State of Tennessee, Department of Treasury
51
State of Tennessee, Department of Treasury
Tennessee
$2.86M +$3.32M +49,518 New
GGHC
52
Gilder Gagnon Howe & Co
New York
$2.82M -$2.51M -37,467 -43%
PI
53
Putnam Investments
Massachusetts
$2.69M
TCM
54
Tekla Capital Management
Massachusetts
$2.68M +$3.12M +46,500 New
CS
55
Credit Suisse
Switzerland
$2.67M +$1.61M +24,021 +108%
GCP
56
GSA Capital Partners
United Kingdom
$2.61M +$3.03M +45,185 New
RPAM
57
Rhenman & Partners Asset Management
Sweden
$2.6M +$670K +10,000 +29%
CC
58
CQS Cayman
Cayman Islands
$2.43M -$6.9M -102,900 -71%
SAM
59
Shikiar Asset Management
New York
$2.42M +$1.01M +15,000 +56%
CNB
60
City National Bank
California
$2.38M +$84.4K +1,260 +3%
CWG
61
C WorldWide Group
Denmark
$2.1M +$2.35M +35,000 New
Barclays
62
Barclays
United Kingdom
$2.04M +$2.34M +34,956 +4,041%
BJ
63
BlackRock Japan
Japan
$1.96M +$2.24M +33,481 +7,859%
Swiss National Bank
64
Swiss National Bank
Switzerland
$1.92M +$154K +2,300 +7%
NFA
65
Nationwide Fund Advisors
Ohio
$1.91M +$1.26M +18,832 +132%
ProShare Advisors
66
ProShare Advisors
Maryland
$1.89M +$355K +5,302 +19%
Charles Schwab
67
Charles Schwab
California
$1.81M +$297K +4,438 +17%
CCM
68
Cadence Capital Management
Massachusetts
$1.78M +$2.07M +30,830 New
PVI
69
Pura Vida Investments
New York
$1.59M -$1.11M -16,600 -38%
Axa
70
Axa
France
$1.55M +$127K +1,899 +8%
BIM
71
BlackRock Investment Management
Delaware
$1.52M -$217K -3,231 -11%
California Public Employees Retirement System
72
California Public Employees Retirement System
California
$1.47M
TAM
73
Tocqueville Asset Management
New York
$1.38M +$620K +9,250 +63%
Bank of Montreal
74
Bank of Montreal
Ontario, Canada
$1.35M +$1.32M +19,638 +515%
B
75
Baird
Wisconsin
$1.35M +$1.57M +23,356 New

KITE Hedge Fund Activity: Q1 2015 in Review

148 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q1 2015, worth a combined $1.47B — up 24% from $1.18B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new KITE positions and 18 closed out — a net gain of 33 holders — while 56 added to existing stakes and 31 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $85M. The largest seller was Silver Rock Financial, cutting an estimated $19.9M.

  • 148 institutional investors held Kite Pharma, Inc. (KITE) as of Q1 2015, up from 116 in Q4 2014.
  • Funds reported $1.47B of Kite Pharma, Inc. stock for Q1 2015, up 24% quarter-over-quarter.
  • 51 funds opened new Kite Pharma, Inc. positions in Q1 2015 and 18 closed out, a net change of +33 holders.
  • The largest Kite Pharma, Inc. buyer in Q1 2015 was Capital Research Global Investors, an estimated $85M added.
  • The largest Kite Pharma, Inc. seller in Q1 2015 was Silver Rock Financial, an estimated $19.9M sold.

Based on aggregated 13F filings for Q1 2015.